A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

Duration of Response

Applicable to complete or partial response participants. DoR was defined as the time from the first documented date of complete or partial response until the date of the disease progression or death from any causes.

Time frame: Baseline up to data cut-off(up to approximately 3 years)

Progression-free survival

Progression-free survival was defined as the time from the date of randomization until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Time frame: Baseline up to data cut-off(up to approximately 3 years)

Overall survival

Percentage of participants with complete or partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

Time frame: Baseline up to data cut-off(up to approximately 3 years)